EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	309.09B -39.4%
Revenue (ttm)	96.04B +62.4%
Net Income	24.87B
EPS	n/a
Shares Out	36.75M
PE Ratio	12.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,887
Open	8,330.00
Previous Close	8,320.00
Day's Range	8,330.00 - 8,500.00
52-Week Range	6,950.00 - 17,700.00
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error